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OBJECTIVE — Urinary liver-type fatty acid-binding protein (u-LFABP) is a marker of tubu-
lointerstitial inﬂammation and has been shown to be increased in patients with type 1 diabetes
and is further increased in patients who progress to micro- and macroalbuminuria. Our aim was
to evaluate u-LFABP as a predictor of progression to micro- and macroalbuminuria in type 1
diabetes.
RESEARCH DESIGN AND METHODS — From an inception cohort of 277 patients,
u-LFABP, adjusted for urinary creatinine (enzyme-linked immunosorbent assay), was measured
in 24-h urine samples from 165 normoalbuminuric patients 9.6  3.5 (mean SD) years after
onset of type 1 diabetes. The outcome measured was development of persistent micro- or
macroalbuminuria or death.
RESULTS — Patients were followed for a median of 18 (range 1–19) years; 39 progressed to
microalbuminuria, 8 of those progressed further to macroalbuminuria, and 24 died. In a Cox
regression model, baseline log u-LFABP levels predicted the development of microalbuminuria,
adjusted for known risk factors (sex, age, A1C, systolic and diastolic blood pressure, albumin
excretionrate,serumcreatinine,andsmoking)(hazardratio[HR]2.3[95%CI1.1–4.6])andlog
u-LFABP predicted mortality (adjusted HR 3.0 [1.3–7.0]). u-LFABP (above versus below the
median) predicted the development of macroalbuminuria (adjusted HR 2.6 [1.2–5.4]). As a
continuous variable, u-LFABP tended to predict macroalbuminuria (HR 1.9, P  0.2), but
numbers were small.
CONCLUSIONS — High levels of the tubular inﬂammation marker u-LFABP predict the
initiation and progression to diabetic nephropathy and all-cause mortality, independent of
urinary albumin excretion rate and other established risk factors.
Diabetes Care 33:1320–1324, 2010
D
uring the past few decades the pre-
vention and treatment of late com-
plications in diabetes have
improved dramatically. The focus on pre-
vention of late diabetes complications has
changed and now involves tight glycemic
control, reducing blood pressure, and
lipid lowering (1), but, despite these ef-
forts, diabetic patients still develop
complications.
Approximately 30–40% of all pa-
tients with diabetes develop diabetic ne-
phropathy (1), and this is the leading
cause of end-stage renal disease in the
Western world. In addition, diabetic ne-
phropathy is associated with a higher risk
of other complications (cardiovascular
disease, neuropathy, and retinopathy)
andwithanincreaseinall-causemortality
(2).
It is known that tubulointerstitial
damage plays an important role in dia-
betic nephropathy (3). Therefore, it
would potentially be beneﬁcial if albu-
minuria, as a marker of glomerular dam-
age, could be supplemented by a marker
oftubulardamagetoprovideamorecom-
plete status of the kidney injury. This
couldhelpusﬁrsttomoreaccuratelypre-
dict the patients at risk of developing di-
abetic nephropathy and second to
provide a better and possibly different
treatment for diabetic nephropathy.
Liver-type fatty acid-binding protein
(LFABP) is an intracellular carrier protein
that is expressed in the proximal tubules
in the human kidney and the liver (4). It
has been demonstrated to be a marker of
tubular damage (5).
Previously we have, in a cross-
sectional setting, shown that urinary (u)-
LFABP is increased in diabetic patients,
even before they develop signs of glomer-
ular damage, microalbuminuria or mac-
roalbuminuria (6). This indicates that
tubulardamageispresentatanearlystage
of diabetic kidney damage, even before
thedevelopmentofmicroalbuminuria.u-
LFABP has, to our knowledge, not yet
been studied in a prospective cohort
study in type 1 diabetic patients.
To extend our previous cross-
sectional ﬁndings we have evaluated the
prognosticvalueofu-LFABPinaprospec-
tive study of type 1 diabetic patients who
were still in a normoalbuminuric state.
We have thereby been able to investigate
whether u-LFABP contributes further to
the established predictors for develop-
ment of microalbuminuria or macroalbu-
minuria and the risk of death.
RESEARCH DESIGN AND
METHODS— We recruited an incep-
tion cohort of 277 patients from the out-
patient clinic at Steno Diabetes Center
from1979to1984foraprospectivestudy
of risk factors for development of compli-
cations. Figure 1 shows the design of the
study and a ﬂow chart. The patients had
newly diagnosed type 1 diabetes. They
were treated according to guidelines de-
scribed earlier (7) and were followed
yearly with blood and urine samples (8).
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1990 were lost, so in our analyses we in-
cluded urine samples from 1990 and on-
ward. Urine samples were available for
204 patients and of these 165 patients
were normoalbuminuric. In 2008 we de-
cided to analyze these urine samples for
u-LFABP. u-LFABP was measured in the
ﬁrst urine sample available after 1990,
9.63.5years(meanSD)afteronsetof
type 1 diabetes, and this was considered
baseline in the present study (Fig. 1).
Hereafter, the patients were followed re-
gardingendpointsforamedian(range)of
18(1–19)years.Theprimaryoutcomesin
our study were time to development of
microalbuminuria or macroalbuminuria
ordeathandwereevaluatedfromthetime
of the patients’ ﬁrst urine sample after
1990 and until 2008 or the last available
urinesampleinpatientslosttofollow-up.
Vital status was assessed in 2008 in the
NationalRegistryforallpatients.Allclin-
ical baseline data were calculated as a
mean of observations from the baseline
year for each patient.
As far as possible, urinary albumin
excretionper24hwasmeasuredyearlyin
each patient. Persistent microalbumin-
uria and persistent macroalbuminuria
were deﬁned as a urinary albumin excre-
tionrate(UAER)between30and300and
300 mg/24 h, respectively, in at least
two of three consecutive samples. All




cury sphygmomanometer and was per-
formed with the patient in a seated
position after 10 min of rest. Smoking
historywasdeterminedviaquestionnaire,
and patients were classiﬁed as smokers if
they were smoking 1 cigarette per day.
Urine samples were stored at 20°C
until u-LFABP analysis in 2009. u-LFABP
was measured in a two-step sandwich en-
zyme-linked immunosorbent assay (9)
and adjusted for u-creatinine. The inter-
and intra-assay variations was 6.8 and
8.2%, respectively.
All patients provided informed con-
sent for the participation in the study.
Statistical analysis
Data are means  SD for the normally
distributed variables. Variables with
skewed distribution are given as geomet-
ric means (95% CI). Cumulative inci-
dences of microalbuminuria and
macroalbuminuria were calculated using
Coxregressionanalyses.InTable1differ-
ences between groups are analyzed using
ANOVA.
ACoxmodelforeachofthethreeend
points (development of microalbumin-
uria, development of macroalbuminuria,
ordeath)wasanalyzedinall165patients.
Microalbuminuria was most frequent but
was a surrogate end point, and thus we
analyzed the development of macroalbu-
minuria separately. If a patient was cate-
gorized as “microalbuminuric” or
“macroalbuminuric” (two of three sam-
ples), heorshewould not be recategorized
if they later regressed in albuminuria. Pa-
tients were followed to 2008 or were cen-
sored at time of death. Patients who were
lost to follow-up were counted in the
analyses using the results of their last
available urine sample. By using the Na-
Figure 1—Design of the study.
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for all patients by the end of 2008.
A Cox regression model was used to
analyze u-LFABP as an explanatory vari-
able for the development of microalbu-
minuria and macroalbuminuria or death.
Subsequently the model was adjusted for
knownriskfactors:sex,age,A1C,systolic
and diastolic blood pressure, UAER, se-
rum creatinine, and smoking. Schoenfeld
residuals were plotted against time to test
for violation of the proportional hazards
assumption, and linearity of the log haz-
ard function was assessed by plotting the
Martingale residuals against the covari-
ates. We looked for interaction between
u-LFABP and sex, A1C, or urinary albu-
min-to-creatinine ratio but found no evi-
dence of interaction. Although the
number of variables can be discussed, we
found the model to work well for mi-
croalbuminuria with the listed and usu-
allyappliedcovariates.Modelswithfewer
variables gave very similar hazard ratios
(HRs) for predicting microalbuminuria;
subsequently we applied the same model
to the other end points.
u-LFABP is reported as a categorical
variable in Fig. 2 for the presentation of a
Kaplan-Meierplot.Receiveroperatingchar-
Table 1—Baseline characteristics of the 165 normoalbuminuric type 1 diabetic patients who had their u-LFABP measured in 1990 or later,




microalbuminuria Macroalbuminuria Progressors P value*
n (male/female) 62/64 22/9 6/2 28/11 0.05
Age (years) 37  12 41.7  2.4 43  94 1  15 0.18
Diabetes duration (years) 8.6  3.4 8.4  1.8 12.1  4.5 9.0  2.8 0.05
Systolic blood pressure (mmHg) 122  15 128  16 138  20 130  17 0.02
Diastolic blood pressure (mmHg) 77  87 9  98 6  14 81  10 0.01
UAER (mg/24 h) 8 (7–9) 11 (8–14) 12 (7–20) 11 (9–14) 0.02
A1C (%) 8.2  1.1 8.6  1.7 9.1  0.9 8.7  1.6 0.02
Serum creatinine (mol/l) 72  11 69  12 70  13 69  12 0.48
u-LFABP/creatinine (pg/ml)/(mg/dl) 9.6 (7.8–11.8) 13.4 (8.4–21.3) 12.6 (8.4–21) 13.2 (8.8–19.9) 0.35
Data are means  SD or geometric means (95% CI). The microalbuminuria group does not include patients who later developed macroalbuminuria. Progressors
include those who progressed to microalbuminuria and macroalbuminuria. *Overall difference between normoalbuminuric, microalbuminuric, and macroalbu-
minuric groups compared by ANOVA.
Figure2—Kaplan-Meierplot:elevatedbaselineu-LFABPlevelsin165normoalbuminurictype1diabeticpatientspredictprogressiontomicroalbu-
minuria. Quartiles with limits: u-LFABP/creatinine: 4.7, 10.9 and 21.3 (pg/ml)/(mg/dl). P  0.02 for overall difference.
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(SPSS,Chicago,IL),assumingnonparamet-
ricdistributionofparametersforSEofarea.
Statistical signiﬁcance was assumed
for P 	 0.05. Data were analyzed using
SPSS 15.0.
RESULTS— At baseline, 165 patients
of the 204 patients followed since 1979–
1984 were persistently normoalbumin-





were followed for a median (range) of 18
(1–19) years. Successful follow-up until
the end point or year 2008 was available
in90.3%ofallpatients.Duringfollow-up
to 2008, 39 patients had developed per-
sistent microalbuminuria, and of these 8
patients progressed further to persistent
macroalbuminuria. During follow-up, 24
patients died. The cumulative incidence
of microalbuminuria was mean 27%
(95% CI 20–35), of macroalbuminuria
was 6% (2–10), and of death was 17%
(11–23).
Baseline characteristics of the pa-
tients, when divided into groups accord-
ing to the later development of
microalbuminuria and macroalbumin-
uria or persistent normoalbuminuria, can
be seen in Table 1. Patients who later de-
velopedmicroalbuminuriaormacroalbu-
minuria had higher systolic and diastolic
bloodpressurethanthepatientswithper-
sistent normoalbuminuria (P 	 0.05).
A1Cwasprogressivelygreaterinthemac-
roalbuminuric and microalbuminuric
groups than in the normoalbuminuric
group (P  0.02). UAER was also in-
creased in the patients later developing
microalbuminuria or macroalbuminuria;
however, there were no signiﬁcant differ-
ence between the groups. As demon-
stratedinTable1,u-LFABPwasincreased
in the microalbuminuric and macroalbu-
minuric patients compared with the pa-
tients with persistent normoalbuminuria;
however, this result was not statistically
signiﬁcant (P  0.17 and P  0.52).
In a Cox regression model (Table 2),
baselinelogu-LFABPlevelspredictedmi-
croalbuminuriawhenadjustedforknown
risk factors (age, sex, A1C, systolic and
diastolic blood pressure, UAER, serum
creatinine,andsmoking)withaHRof2.3
(95% CI 1.1–4.6). When u-LFABP was
analyzed as a predictor of microalbumin-
uria using receiver operating curve analy-
sis, we found that with addition of
u-LFABP to the known risk factors (age,
sex, A1C, systolic and diastolic blood
pressure, UAER, serum creatinine, and
smoking), the area under the curve in-
creased only slightly from 0.80 (0.71–
0.89) to 0.81 (0.72–0.91).
As demonstrated in a Kaplan-Meier
plot in Fig. 2, u-LFABP divided into quar-
tiles predicts the development of mi-
croalbuminuria (P  0.024). The HR from
theﬁrsttofourthquartileis5.8(P0.004).
As a continuous variable, u-LFABP
tended to predict the development of
macroalbuminuria (HR 1.9), but this re-
sult was not statistically signiﬁcant (P 
0.2), most likely because numbers were
small (n  8). When analyzed as a cate-
gorical variable u-LFABP [above versus
below the median  10.9 (pg/ml)/(mg/dl
creatinine)]predictedthedevelopmentof
macroalbuminuria (HR 2.6 [95% CI 1.2–
5.4]; adjusted for risk factors, see above).
During follow-up, 24 patients died.
As a continuous variable, high levels of
u-LFABP were associated with a signiﬁ-
cant increased risk of mortality (adjusted
HR 3.0 [95% CI 1.3–7.0].
CONCLUSIONS— In our study u-
LFABP predicted the future development
of microalbuminuria and death in nor-
moalbuminuric type 1 diabetic patients
from an inception cohort study. The pa-
tients were followed for a median of 18
years, and the cumulative incidence of
microalbuminuria and macroalbumin-
uria was mean 27% (95% CI 20–35) and
6% (2–10), respectively.
Previously, we demonstrated that u-
LFABPisincreasedalreadyinnormoalbu-
minuric type 1 diabetic patients,
indicating a “tubular phase” in the patho-
genesis to diabetic kidney damage (6).
However, this was done in a cross-
sectional study, which in its design has
somelimitations,andthusnothingcanbe
concluded on the time perspective be-
tween elevated u-LFABP and progression
to microalbuminuria and macroalbumin-
uria.Withthedesignofthepresentstudy,
we have been able to demonstrate that
high levels of u-LFABP are evident even
beforethedevelopmentofmicroalbumin-
uria and hence at an early state where the
glomerular damage is not detectable (al-
bumin excretion rate not elevated), but
where the tubules are affected (elevated
u-LFABP). In Table 2 it is seen that ele-
vated urinary albumin excretion in the
normal range is also a strong predictor of
progression to microalbuminuria. How-
ever, our aim was to supplement urinary
albumin as a measure rather than replace
it. If patients are followed over time, it is
possible that changes in the markers
within the normal range could add pre-
dictive value; however, we aimed to im-
prove prediction of prognosis from a
single point in time.
In an abstract presented at the Amer-
ican Society of Nephrology meeting in
2009 Kamijo et al. (10) reported that u-
LFABP predicts a decrease in estimated
glomerular ﬁltration rate in type 2 dia-
betic patients with diabetic nephropathy.
This ﬁnding supports our results and in-
dicates that u-LFABP is a promising
marker in not only type 1 but also type 2
diabetic patients. In a study of nondia-
betic patients with chronic kidney dis-
ease, similar results were found: kidney
function in patients with u-LFABP levels
above the median deteriorated faster than
that in patients with u-LFABP below the
median during 1 year of follow-up (11).
Tamm-Horsfall protein, another marker
of tubular damage, is produced in the
thick ascending limb of Henle. Tamm-
Horsfallproteinhasbeenfoundtobepre-
dictive of cardiovascular death and
uremia in type 1 but not type 2 diabetic
patients (12). This ﬁnding again supports
Table 2—Cox regression: u-LFABP predicts the development of microalbuminuria when ad-
justed for known risk factors
Odds ratio (95% CI) P value
Sex (male) 4.19 (1.62–10.87) 0.003
Age (year) 1.02 (0.99–1.05) 0.274
A1C (%) 2.00 (1.36–2.95) 	0.001
Systolic blood pressure (mmHg) 1.03 (0.995–1.06) 0.100
Diastolic blood pressure (mmHg) 0.99 (0.94–1.04) 0.758
Log (urinary albumin mg/24 h) 12.36 (2.58–59.32) 0.002
Log (u-LFABP ng/ml/urinary creatinine) 2.28 (1.14–4.58) 0.021
Theanalysesincludessex,age,A1C,systolicanddiastolicbloodpressure,UAER,u-LFABP,serumcreatinine
(not shown), and smoking (not shown).
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be added to albuminuria in the risk as-
sessment of the development of diabetic
nephropathy.
In the present study, we found that
u-LFABP predicted death. It is not possi-
ble to deﬁne the causality, but it is most
likely that the effect of u-LFABP is medi-
atedthroughthedevelopmentofelevated
urinary albumin excretion. We found that
patientswhodiedhadasigniﬁcantlyhigher
incidence of microalbuminuria or mac-
roalbuminuria than patients who survived
during follow-up (41 vs. 21%, P  0.027).
By studying renal biopsy specimens
with immunohistochemical staining, it
hasbeenshownthatu-LFABPexcretionis
closely associated with structural and
functional tubular kidney damage (13).
This ﬁnding was conﬁrmed in patients
with chronic kidney disease including
minimal change nephrotic syndrome, ne-
phrosclerosis, lupus nephritis, and dia-
betic nephropathy (14). In a recent
experimental study in transgenic mice, it
has been shown that u-LFABP accurately
reﬂects the degree of tubulointerstitial
damage and is dynamic as a measure; it
increases and decreases, reﬂecting dam-
age and repair of the tubular cells (15). In
accordance with these results, we previ-
ously reported that u-LFABP excretion is
reduced when type 1 diabetic patients
with diabetic nephropathy are treated with
renoprotective treatment such as the ACE
inhibitorlisinopril(6).Thisﬁndingleadsto
speculations on u-LFABP as a monitor of
renoprotective treatment; however, more
studies are needed to conﬁrm this.
Our results show that high levels of
u-LFABP predict the development of mi-
croalbuminuria and diabetic nephropa-
thy.However,thisdoesnotdeterminethe
mechanism or the role of LFABP: it has
been hypothesized that LFABP is a pro-
tective protein (16), but previous studies
have, to our knowledge, not been able to
conﬁrm this hypothesis (17). u-LFABP as
a continuous variable did not predict
macroalbuminuria,butitdidasacategor-
ical variable. Because of the low number
of events (n  8), the analysis has to be
interpreted with caution, but it is in line
with the prediction of microalbuminuria.
The present study has some limita-
tions. The patients only had their u-
LFABP measured in one 24-h urine
sample, and the urine samples were
stored at 20°C for 18 years before
analyses. Another limitation is the loss of
urine samples before 1990 (Fig. 1). How-
ever, this most likely results in a underesti-
mation of the predictive power of u-LFABP
aspatientsmostsusceptibletorenaldisease,
probably having the most tubular damage,
already had developed microalbuminuria
or macroalbuminuria and were excluded.
The strengths of our study are that all pa-
tients were followed for vital status and
90% were followed to 2008 or the devel-
opment of a renal end point.
In summary, we demonstrate that u-
LFABP is elevated at an early stage, even
before any clinical signs of glomerular
damagearedetectable,conﬁrmingthehy-
pothesis of a “tubular phase” in the devel-
opment of diabetic nephropathy.
u-LFABP is seen to be independent pre-
dictor of microalbuminuria and death.
Thus, u-LFABP may be used as an indica-
tor of tubular damage early in the course
of diabetes and therefore may ﬁnd a place
as a new tool in the prediction of diabetic
nephropathy. However, further studies
are needed for conﬁrmation.
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